Temporal relationships between systemic lupus erythematosus and comorbidities.

Objective To examine the burden of comorbidities prior to and after the diagnosis of SLE and its impact on mortality. Methods We identified 1605 incident cases of SLE and 6284 matched controls from the UK primary care. The risks of comorbidities before (prevalence; odds ratios) and after SLE diagnosis (incidence; hazard ratios) and the impact of comorbidities at diagnosis on all-cause mortality were estimated. Results At diagnosis, SLE was associated with adjusted odds ratios (95% CI) of 2.25 (1.97-2.56), 3.37 (2.49-4.57) and 3.54 (1.89-6.63) for a Charlson comorbidity index of 1-2, 3-4 and ≥5, respectively. Following diagnosis, SLE also associated with increased risk of developing any comorbidity with an adjusted hazard ratio (95% CI) of 1.30 (95% CI, 1.13-1.49). At diagnosis, SLE was associated with a greater risk of cancer, cardiovascular, renal, liver, rheumatological and neurological diseases as well as depression, anaemia and psoriasis. Risks of developing incident comorbidity in the categories of neoplasm, cardiovascular, genitourinary, metabolic/endocrine, gastrointestinal and hepatic diseases, chronic pulmonary diseases, musculoskeletal/connective tissue and neurological diseases were higher in SLE patients. People with SLE had higher mortality risk compared with controls, with adjusted hazard ratio of 1.91 (95% CI, 1.62-2.26); after further adjusting for comorbidities this reduced to 1.64 (1.37-1.97). Comorbidities at SLE diagnosis accounted for 27.6% of the apparent difference in mortality between SLE patients and matched controls. Conclusion People with SLE have increased risks of multiple comorbidities both prior to and after diagnosis and this contributes significantly to all-cause mortality.

[1]  Ning Li,et al.  46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013 , 2017, Annals of Internal Medicine.

[2]  L. See,et al.  Risk of end‐stage renal disease in systemic lupus erythematosus patients: a nationwide population‐based study , 2016, International journal of rheumatic diseases.

[3]  M. Doherty,et al.  Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. , 2016, Rheumatology.

[4]  M. Doherty,et al.  Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999–2012 , 2015, Arthritis care & research.

[5]  M. Doherty,et al.  Comorbidities in patients with gout prior to and following diagnosis: case-control study , 2014, Annals of the rheumatic diseases.

[6]  M. Doherty,et al.  The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012 , 2014, Annals of the rheumatic diseases.

[7]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[8]  F. Bessone,et al.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. , 2014, World journal of hepatology.

[9]  J. Aviña-Zubieta,et al.  Overall and Cause‐Specific Mortality in Patients With Systemic Lupus Erythematosus: A Meta‐Analysis of Observational Studies , 2014, Arthritis care & research.

[10]  K. Bhaskaran,et al.  Completeness and usability of ethnicity data in UK-based primary care and hospital databases , 2013, Journal of public health.

[11]  D. Isenberg,et al.  Cancer complicating systemic lupus erythematosus – a dichotomy emerging from a nested case-control study , 2013, Lupus.

[12]  D. Gladman,et al.  Cancer risk in systemic lupus: an updated international multi-centre cohort study. , 2013, Journal of autoimmunity.

[13]  Jinoos Yazdany,et al.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis , 2012, Arthritis care & research.

[14]  P. Rose,et al.  Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[15]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[16]  L. Smeeth,et al.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.

[17]  D. Scott,et al.  Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. , 2009, Arthritis and rheumatism.

[18]  F. Mowat,et al.  Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database , 2009, British journal of haematology.

[19]  C. Mok,et al.  Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus , 2009, Scandinavian journal of rheumatology.

[20]  C. Gordon,et al.  Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future – the EULAR recommendations for the management of SLE and the use of end-points in clinical trials , 2008, Lupus.

[21]  M. Petri Sex hormones and systemic lupus erythematosus , 2008, Lupus.

[22]  D. Wallace Lupus: The Essential Clinician's Guide , 2008 .

[23]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[24]  Sinisa Pajevic,et al.  Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. , 2006, Arthritis and rheumatism.

[25]  M. Urowitz,et al.  Mortality in systemic lupus erythematosus. , 1987, Arthritis and rheumatism.

[26]  R. Cervera,et al.  Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. , 2005, Rheumatology.

[27]  C. Gordon,et al.  Prevalence and predictors of fragility fractures in systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[28]  C. Mok,et al.  Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. , 2004, The American journal of medicine.

[29]  M. Neale,et al.  The Validity of the Neale and Kendler Model-Fitting Approach in Examining the Etiology of Comorbidity , 2004, Behavior genetics.

[30]  R. Schlienger,et al.  Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. , 2004, The American journal of cardiology.

[31]  J. Birkmeyer,et al.  Surgeon volume and operative mortality in the United States. , 2003, The New England journal of medicine.

[32]  I. Bruce,et al.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. , 2003, Arthritis and rheumatism.

[33]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[34]  D. Isenberg,et al.  Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades , 2002, Annals of the rheumatic diseases.

[35]  D. Gladman,et al.  Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. , 2001, The Journal of rheumatology.

[36]  D. Isenberg,et al.  Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. , 2000, Rheumatology.

[37]  D. Dunlop,et al.  Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. , 1999, Arthritis and rheumatism.

[38]  M. Ward Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[39]  N. Goel,et al.  Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course , 1998 .

[40]  H. Jick,et al.  Omeprazole, other antiulcer drugs and newly diagnosed gout. , 2003, British journal of clinical pharmacology.

[41]  N. Rothfield,et al.  Racial aspects of comorbidity in systemic lupus erythematosus. , 1996, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[42]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[43]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[44]  H Jick,et al.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.

[45]  A R Feinstein,et al.  THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. , 1970, Journal of chronic diseases.

[46]  Rowell Nr,et al.  Lupus erythematosus. Analysis of the sex- and age-distributions of the discoid and systemic forms of the disease in different countries. , 1970 .

[47]  N. Rowell,et al.  Lupus erythematosus. Analysis of the sex- and age-distributions of the discoid and systemic forms of the disease in different countries. , 1970, Acta dermato-venereologica.